CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Profitability
This table compares CollPlant Biotechnologies and Akebia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -683.68% | -218.81% | -139.28% |
| Akebia Therapeutics | -13.54% | -88.88% | -7.74% |
Valuation & Earnings
This table compares CollPlant Biotechnologies and Akebia Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $389,000.00 | 16.93 | -$11.49 million | ($14.50) | -0.31 |
| Akebia Therapeutics | $219.06 million | 1.16 | -$5.34 million | ($0.11) | -8.32 |
Akebia Therapeutics has higher revenue and earnings than CollPlant Biotechnologies. Akebia Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CollPlant Biotechnologies has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for CollPlant Biotechnologies and Akebia Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
CollPlant Biotechnologies presently has a consensus target price of $120.00, indicating a potential upside of 2,531.58%. Akebia Therapeutics has a consensus target price of $3.90, indicating a potential upside of 325.90%. Given CollPlant Biotechnologies’ higher probable upside, research analysts plainly believe CollPlant Biotechnologies is more favorable than Akebia Therapeutics.
Insider & Institutional Ownership
21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Akebia Therapeutics beats CollPlant Biotechnologies on 9 of the 14 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
